Med24
peptide-development 1. 10. 2026 • 2 min read • Nutrition in clinical practice : official publication of the American Society for Parenteral and Ent

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists have significantly impacted the treatment of type 2 diabetes and obesity. Gastrointestinal adverse events represent a primary limitation of these therapies, frequently leading to discontinuation. This expert review synthesizes data from randomized controlled trials, observational studies, meta-analyses, and pharmacovigilance information to detail the incidence, mechanisms, and clinical implications of these events across various agents.

Gastrointestinal Adverse Events

Nausea, vomiting, diarrhea, and constipation are common, occurring in approximately 30%-50% of patients, particularly during initiation and dose adjustments. These events are generally mild to moderate and can be managed through dose titration and dietary changes. Mechanisms include delayed gastric emptying, activation of emetic pathways, altered intestinal motility, and the physiological effects of rapid weight loss. Acute pancreatitis has been observed, but randomized trial data do not demonstrate a class-level excess risk. Pharmacovigilance signals are most likely due to diagnostic misclassification rather than a causal relationship. Cholelithiasis shows a probable association, largely mediated by weight loss. Peri-procedural data indicate increased residual gastric volume without confirmed aspiration events.

Sponsored content

Emerging Agents and Future Directions

Preliminary data on pipeline agents – retatrutide, survodutide, and cagrilintide-semaglutide – suggest a similar GI adverse event profile to currently approved therapies, though evidence remains limited. A proactive, patient-centered approach is recommended to optimize adherence, safety, and clinical outcomes with these expanding therapeutic options.

Original Scientific Source
Nutrition in clinical practice : official publication of the American Society for Parenteral and Ent
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement